Image Image Image Image Image Image Image Image Image Image
Доступ
Идти наверх

Идти наверх

The Institut de la Màcula participates in a new clinical trial for exudative AMD with a state-of-the-art drug

10/12/2019 · новости
IDLM-72

The Institut de la Màcula has begun a new clinical trial in the treatment of age-related macular degeneration (AMD) in its exudative form. It is now in the process of selecting candidates who will enjoy free access to a state-of-the-art drug and an innovative treatment

This December, the Institut de la Màcula has started a new clinical trial, TALON*, with a state-of-the-art and long-lasting drug indicated for age-related macular degeneration (AMD) in its exudative form. This is a phase IIIb, multicentre, randomised trial with double masking of two groups.

The main aim is to assess the efficacy and safety of brolacizumab in comparison with aflibercept in reference to the results of visual acuity at 28 and 32 weeks with regard to the baseline, but also in terms of the duration of the intervals between treatment.

The trial, of a sixteen-month duration, is now in the candidate selection process. Clinical trials only accept a limited number of patients and are subject to rigorous inclusion criteria:

  • Patients of over 50 with active choroidal neovascularisation secondary to AMD.
  • Those who have not received any prior treatment to the study eye.
  • Visual acuity should be between 38 and 83 letters (approximate Snellen equivalent of 20/25 to 20/200).

Participating in this clinical trial enables free access to innovative treatment, with personalised and cutting-edge care by expert ophthalmologists. It is also the only way of accessing a new drug that is not yet available to the general public but has already shown very good results in previous studies.

Brolacizumab (RTH258) is a humanised single-chain antibody fragment (scFv) that is responsible for blocking the action of VEFG-A, preventing it from binding to its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, meaning that its principal function is anti-angiogenic. Brolacizumab is designed for ophthalmic use and administered by intravitreal injection.

Those interested in participating can send their details using the form below and our team of professionals will then call them to assess their eligibility.

AMD is one of the main diseases under investigation in the field of ophthalmology. Globally, the leading ophthalmological centres are working on the mission of improving current treatments for exudative AMD, advancing in prevention and in techniques of approach and discovering treatment for atrophic AMD. The Institut de la Màcula, in close collaboration with the Barcelona Macula Foundation, forms part of a group that aspires to reverse the vision pathologies that until recently were developing inexorably.

* Institut Registration Code: E08607500. Clinical trial No. EudraCT 2019-000716-28. Clinical trial authorised by the Spanish Agency of Medicines and Medical Devices (AEMPS) and the Drug Research Ethics Committee (CEIm) of the Quironsalud Hospital Group in Barcelona.

Экссудативная или влажная ВМД
Last modified: 20 February, 2020 - 10:08